New insights into pelareorep’s immune system-related mechanism of action demonstrate that it stimulates an innate immune response which, in turn, triggers adaptive anti-tumor immunity
Specificity for tumor cells relative to normal cells likely results from impaired viral detection/interferon responses in malignant cells
SAN DIEGO and CALGARY, Alta., March 17, 2022 /CNW/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The article, titled “Oncolytic virus treatment differentially affects CD56weak and CD56brilliant NK cell subsets live and Regulates a Spectrum of Human NK Cell Activity,” was published in collaboration with researchers from several prestigious institutions, including the University of Leeds School of Medicine and the Cancer Research Institute, London. A link to the document can be found by clicking here.
Described in the document are in vitro studies evaluating the effects of pelareorep on Natural Killer (NK) cells; and analyzes of blood samples from patients with colorectal liver metastases taken before and after treatment with pelareorep. The results showed that pelareorep treatment resulted in the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity. Beneficial effects of pelareorep have been observed both in patient samples and in vitro and were mediated by interferon type 1 (IFN-1) signaling, a key pathway involved in tumor cell immunoregulation and recognition.
“These important results demonstrate both the innate and adaptive immunological mechanism of action of pelareorep, and we are pleased to have published them in such a prestigious, peer-reviewed journal,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech and co-author of the article. “Reviewing these results, along with previous clinical data demonstrating the ability of pelareorep to activate T cells while promoting their infiltration into tumors, we find that pelareorep delivers a robust and coordinated anti-cancer immune response, driven by both innate and adaptive immune systems. we will continue to leverage the immunotherapeutic effects of pelareorep as we pursue its development as an enabling technology for a wide range of immunotherapeutic agents in breast cancer and other oncology indications with high unmet need. »
The patient samples evaluated in the publication were from a completed clinical window of opportunity study evaluating pelareorep in colorectal cancer patients with liver metastases. Patients received between one and five doses of pelareorep prior to scheduled surgery to resect metastases. Blood samples were taken before and at several time points after treatment with pelareorep. Additional details about the trial, as well as previously reported results, are available in previous peer-reviewed publications.1.2.
1. Adair RA, Roulstone V, Scott KJ, et al. Sci Transl Med. 2012;4(138):138ra77. doi:10.1126/scitranslmed.3003578
2. El-Sherbiny YM, Holmes TD, Wetherill LF, et al. Clin Exp Immunol. 2015;180(1):98-107. doi:10.1111/cei.12562
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously administered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype – turning “cold” tumors into “hot” – through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it progresses to a registration study in metastatic breast cancer. For more information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are hereinafter collectively referred to as “forward-looking statements”). Forward-looking statements in this press release include statements regarding Oncolytics’ belief in the potential and benefits of pelareorep as a cancer treatment; Oncolytics’ plans to move forward with a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics’ business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief regarding future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement, expectation or conviction will be achieved. These forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics’ actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the effectiveness of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics’ ability to successfully commercialize pelareorep, uncertainties related to research and development of pharmaceutical products, uncertainties related to the regulatory process and general changes in the economic environment. In particular, we may be impacted by business disruptions resulting from the COVID-19 coronavirus, including delays and disruptions in operations, manufacturing supply chain, clinical trials and project development, labor shortages, travel and shipping disruptions and closures (including due to government regulatory and preventative measures). It is unknown if and how oncolytics may be affected if the COVID-19 pandemic persists for an extended period. We may incur expenses or delays related to such events beyond our control, which could have a material adverse effect on our business, results of operations and financial condition. Investors should consult the quarterly and annual filings of Oncolytics with securities commissions in Canada and the United States for additional information on the risks and uncertainties associated with forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update these forward-looking statements, except as required by applicable law.
View original content: https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-publication-of-preclinical-and-patient-data-demonstrating-pelareoreps-stimulation-of-natural-killer-cell – anticancer-activity-301504761.html
SOURCE Oncolytics Biotech® Inc.
View original content: http://www.newswire.ca/en/releases/archive/March2022/17/c5251.html